Integrated Genetics/Knoll
Executive Summary
Integrated Genetics entered into license and development agreement with the German firm BASF for tissue-type plasminogen activator (tPA). The agreement calls for Integrated Genetics to produce tPA for clinical trials, expected to begin in 1986, and to research "other proteins" over a several year period. The firm indicated that BASF will market the final products through its Knoll subsidiary, in all parts of the world except Japan and the Far East, which are covered under a prior agreement with the Japanese firm, Toyobo.